Fund 3
Vesalius Biocapital III

This fund, launched in May 2017 and finally closed in May 2019, targets later-stage European life science companies in drug development, medtech, diagnostics and eHealth / mHealth.

€120 million of commitments secured

The fund secured over €120 million of commitments; final closing took place in May 2019.



News for Vesalius Biocapital Fund 3

CatalYm in Nature Communications
read more
OncoDNA: Closing Round C financing
read more
Memo Therapeutics: U.S. Pivotal Phase II/III
read more